{
    "2019-01-07": [
        [
            {
                "time": "2019-01-01",
                "original_text": "医药生物行业2019年1月报:带量采购背景下的投资思路与配置方向",
                "features": {
                    "keywords": [
                        "医药生物",
                        "带量采购",
                        "投资思路",
                        "配置方向"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-01-01",
                "original_text": "医药生物行业2019年度A+H策略报告:大破大立,不经一番寒彻骨,怎得梅花扑鼻香",
                "features": {
                    "keywords": [
                        "医药生物",
                        "A+H策略",
                        "大破大立",
                        "寒彻骨",
                        "梅花扑鼻香"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}